Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies - McDermott, D F; Motzer, R J; Atkins, M B (J Clin Oncol, 2016)
(suppl; abstr 4507)